HPV Vaccines
Human Papillomavirus (HPV) vaccine is an inactivated (not live) vaccine which protects against four major types of HPV.
These include two types that cause about 70% of cervical cancer and two types that cause about 90% of genital warts. HPV vaccine can prevent most genital warts and most cases of cervical cancer. Protection from HPV vaccine is expected to be long-lasting. But vaccinated women still need cervical cancer screening because the vaccine does not protect against all HPV types that cause cervical cancer.
Routine HPV Vaccination
- HPV vaccine is routinely recommended for girls 11 and 12 years of age
- The HPV4 vaccine (the type recommended for prevention of genital warts in girls) may also be given in three doses to boys aged 9 to 26.
It is important for girls to get HPV vaccine before their first sexual contact -- because they have not been exposed to HPV. For these girls, the vaccine can prevent almost 100% of disease caused by the four types of HPV targeted by the vaccine. However, if a girl or woman is already infected with a type of HPV, the vaccine will not prevent disease from that type. The vaccine is also recommended for girls and women 13 through 26 years of age who did not receive it when they were younger.
- Advances in HPV Vaccine
- HPV Vaccines for Men
- HPV Vaccine risks and controversies
- HPV Vaccine for Women
Related Conference of HPV Vaccines
10th International Conference on Vaccines, Immunology and Clinical Trials
8th International conference on Vaccines, Vaccination and Immunization
HPV Vaccines Conference Speakers
Recommended Sessions
- Cancer Vaccines and Immunotherapy
- Childhood and Maternal Vaccines
- DNA Vaccines
- Hepatitis Vaccines
- HIV/AIDS Vaccines
- HPV Vaccines
- Human Preventive & Therapeutic Vaccines
- Human Vaccines - Infectious & Non Infectious Diseases
- Immunology/Animal Models
- Mucosal Vaccines
- Next-Generation Vaccines Delivery Technologies
- Plant-based Vaccines
- Travel Immunization
- Vaccine Adjuvants
- Vaccine Research & Development
- Vaccine Safety & Efficacy
- Vaccines against Vector-borne Diseases
- Vaccines against Viral & Bacterial Diseases
- Vaccines Business Development
- Vaccines for Older Adults
- Vaccines for Respiratory Diseases
- Veterinary Vaccines
Related Journals
Are you interested in
- Adaptive Immunity and Immune Regulation - Vaccines R&D 2027 (France)
- Adult and Healthy Aging Vaccination - Vaccines-Immunization-2027 (France)
- Advanced Vaccine Research and Innovation - VACCINE CONGRESS 2026 (Japan)
- Advances in Vaccine Research and Development - Vaccines-Immunization-2027 (France)
- Allergy and Clinical Immunology - Vaccines R&D 2027 (France)
- Artificial Intelligence in Vaccine Discovery - Vaccines R&D 2027 (France)
- Artificial Intelligence in Vaccine Research - VACCINE CONGRESS 2026 (Japan)
- Artificial Intelligence, Digital Health and Vaccine Innovation - Vaccines-Immunization-2027 (France)
- Autoimmunity and Immune Disorders - Vaccines R&D 2027 (France)
- Bioinformatics and Computational Immunology - Vaccines R&D 2027 (France)
- Biomarkers in Immunology and Clinical Research - Vaccines R&D 2027 (France)
- Biostatistics and Epidemiology in Vaccine Research - VACCINE CONGRESS 2026 (Japan)
- Biotechnology and Vaccine Engineering - VACCINE CONGRESS 2026 (Japan)
- Cancer Vaccines and Immunotherapy - Vaccines R&D 2027 (France)
- Childhood Vaccination and Routine Immunization - Vaccines-Immunization-2027 (France)
- Clinical Trial Design and Regulatory Affairs - Vaccines R&D 2027 (France)
- Clinical Trials and Vaccine Evaluation - VACCINE CONGRESS 2026 (Japan)
- Clinical Trials in Vaccinology - Vaccines R&D 2027 (France)
- Clinical Vaccinology and Immunization Practice - VACCINE CONGRESS 2026 (Japan)
- Cold Chain, Storage and Vaccine Delivery Systems - Vaccines-Immunization-2027 (France)
- Digital Health in Clinical Trials - Vaccines R&D 2027 (France)
- Emerging & Re-emerging Infectious Diseases - Vaccines R&D 2027 (France)
- Emerging and Neglected Disease Vaccines - Vaccines-Immunization-2027 (France)
- Emerging Trends in Vaccine Science - VACCINE CONGRESS 2026 (Japan)
- Ethical, Legal and Regulatory Aspects of Clinical Research - Vaccines R&D 2027 (France)
- Future of Vaccines and Pandemic Preparedness - Vaccines-Immunization-2027 (France)
- Global Health and Vaccine Equity - VACCINE CONGRESS 2026 (Japan)
- Global Immunization Programmes and Public Health - Vaccines-Immunization-2027 (France)
- Global Vaccination Programs and Public Health - Vaccines R&D 2027 (France)
- HPV Vaccination and Cancer Prevention - Vaccines-Immunization-2027 (France)
- Immunogenetics and Genomic Medicine - Vaccines R&D 2027 (France)
- Immunology and Host Immune Response - VACCINE CONGRESS 2026 (Japan)
- Immunology and Immune System Mechanisms - Vaccines R&D 2027 (France)
- Industrial Vaccine Manufacturing and Scale Up - VACCINE CONGRESS 2026 (Japan)
- Infectious Diseases and Immunization Strategies - Vaccines R&D 2027 (France)
- Influenza, RSV and Respiratory Virus Vaccines - Vaccines-Immunization-2027 (France)
- Innovations in Vaccines, Immunology and Clinical Trials - Vaccines R&D 2027 (France)
- Maternal, Neonatal and Adolescent Immunization - Vaccines-Immunization-2027 (France)
- Monoclonal Antibodies and Biologics - Vaccines R&D 2027 (France)
- mRNA and Nucleic Acid Vaccines - Vaccines-Immunization-2027 (France)
- mRNA, DNA & Viral Vector Vaccines - Vaccines R&D 2027 (France)
- Mucosal and Innate Immunity - Vaccines R&D 2027 (France)
- Nanotechnology in Vaccine Delivery - VACCINE CONGRESS 2026 (Japan)
- Next Generation Vaccines and Emerging Technologies - VACCINE CONGRESS 2026 (Japan)
- Next-Generation Vaccine Technologies - Vaccines R&D 2027 (France)
- Next-Generation Vaccine Technologies - Vaccines-Immunization-2027 (France)
- Pandemic Preparedness and Vaccine Development - Vaccines R&D 2027 (France)
- Pediatric and Adult Immunization - Vaccines R&D 2027 (France)
- Personalized Vaccinology and Precision Immunization - VACCINE CONGRESS 2026 (Japan)
- Precision Immunology and Personalized Vaccines - Vaccines R&D 2027 (France)
- Public Health and Immunization Policy - VACCINE CONGRESS 2026 (Japan)
- Regulatory Affairs and Vaccine Approval Systems - VACCINE CONGRESS 2026 (Japan)
- Regulatory Affairs and Vaccine Policy - Vaccines-Immunization-2027 (France)
- Therapeutic Vaccines - Vaccines R&D 2027 (France)
- Translational Immunology - Vaccines R&D 2027 (France)
- Vaccine Adjuvants and Delivery Systems - Vaccines R&D 2027 (France)
- Vaccine Clinical Trials and Evaluation - Vaccines-Immunization-2027 (France)
- Vaccine Delivery Systems and Formulations - VACCINE CONGRESS 2026 (Japan)
- Vaccine Design and Molecular Biology - VACCINE CONGRESS 2026 (Japan)
- Vaccine Discovery and Development - VACCINE CONGRESS 2026 (Japan)
- Vaccine Equity, Access and Global Health - Vaccines-Immunization-2027 (France)
- Vaccine Hesitancy, Confidence and Public Communication - Vaccines-Immunization-2027 (France)
- Vaccine Immunology and Immune Responses - Vaccines-Immunization-2027 (France)
- Vaccine Manufacturing and Quality Control - Vaccines R&D 2027 (France)
- Vaccine Manufacturing, Quality Control and Scale-Up - Vaccines-Immunization-2027 (France)
- Vaccine Research and Development - Vaccines R&D 2027 (France)
- Vaccine Safety and Pharmacovigilance - VACCINE CONGRESS 2026 (Japan)
- Vaccine Safety, Efficacy & Pharmacovigilance - Vaccines R&D 2027 (France)
- Vaccine Safety, Pharmacovigilance and Adverse Events - Vaccines-Immunization-2027 (France)
- Viral and Bacterial Vaccine Research - VACCINE CONGRESS 2026 (Japan)
